By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Sangamo Therapeutics 

501 Canal Boulevard
Suite F
Richmond  California  94804  U.S.A.
Phone: 510-970-6000 Fax: 510-970-7890


SEARCH JOBS

Sangamo Therapeutics is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has open Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington's disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences.


Key Statistics


Email:
Ownership: Public

Web Site: Sangamo
Employees:
Symbol: SGMO
 



Industry
Biotechnology






Company News
Sangamo (SGMO) And Pfizer (PFE) Announce First Patient Receives Treatment In Phase I/II Clinical Trial Evaluating SB-525 Investigational Gene Therapy For Hemophilia A 8/25/2017 7:44:26 AM
Sangamo (SGMO) Reports Second Quarter 2017 Financial Results 8/10/2017 12:52:44 PM
Sangamo (SGMO) Announces Second Quarter 2017 Conference Call And Webcast 8/3/2017 12:14:50 PM
Sangamo (SGMO) Receives Fast Track Designation From The FDA For SB-318 And SB-913 In Vivo Genome Editing Product Candidates For The Treatment Of MPS I And MPS II 7/14/2017 6:30:45 AM
Sangamo (SGMO) Appoints Roger Jeffs, Ph.D. And Joseph S. Zakrzewski To Its Board Of Directors 6/30/2017 8:43:40 AM
Sangamo (SGMO) Announces Closing Of Public Offering Of Common Stock And Exercise In Full Of Underwriters' Option To Purchase Additional Shares Of Common Stock 6/27/2017 9:07:44 AM
Sangamo (SGMO) Announces Pricing Of $72.5 Million Public Offering Of Common Stock 6/21/2017 8:38:36 AM
Sangamo (SGMO) Announces Proposed Public Offering Of Common Stock 6/21/2017 7:28:04 AM
Sangamo (SGMO) And Pfizer (PFE) Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The EMA 6/7/2017 7:26:12 AM
Sangamo (SGMO) Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy 5/16/2017 9:12:39 AM
12345678910...
//-->